Association of atrial fibrillation and clinical outcomes in adults with chronic kidney disease: A propensity score-matched analysis

Chunxia Zhang, Jingli Gao, Yidan Guo, Aijun Xing, Pengpeng Ye, Yuntao Wu, Shouling Wu, Yang Luo

Abstract

Objective
Atrial fibrillation (AF) is associated with adverse outcomes in the general population, but its impact on patients with chronic kidney disease (CKD) remains unclear. In this study, we assessed the association between AF and risks of all-cause mortality and stroke in Chinese adults with CKD.

Methods
We enrolled adults aged 45 years or older with CKD (defined as an estimated glomerular filtration rate <60 mL/min per 1.73 m² and/or proteinuria identified using the urine dipstick method) from the Kailuan study between 2008 and 2014. AF was identified by 12-lead electrocardiography or hospital discharge diagnostic codes. Mortality data were collected from the provincial vital statistics, and physician-diagnosed ischemic or hemorrhagic stroke was confirmed in the biennial interview.

Results
Among the 21587 CKD adults, 216 patients were identified with AF, the median follow-up duration was 5.21 years (5.69 ± 1.96 years); During follow-up, there were 70 cases of death, and 16 cases of ischemic stroke and 6 cases of hemorrhagic stroke in the participants with AF in comparison with 2572 cases of death and 656 cases of ischemic stroke and 184 cases of hemorrhagic stroke among the participants without AF. After adjustment for potential confounders, AF was associated with an 86% increase in the rate of death (hazard ratio [HR], 1.86; 95% confidence interval [CI], 1.33–2.59, P < 0.001), a 104% increase in the rate of ischemic stroke (HR, 2.04; 95% CI, 1.09–3.83, P = 0.026) and 325% increase in the rate of hemorrhagic stroke (HR, 4.25; 95% CI, 1.74–10.36, P = 0.001). These associations were still consistent and strong after propensity score-matched analysis.
Conclusion
Our study shows that AF is independently associated with increased risk of all-cause mortality, ischemic and hemorrhagic stroke in Chinese CKD adults. Future studies are required to elucidate the physiological mechanisms underlying this association.

Introduction
It is estimated that the prevalence of atrial fibrillation (AF) in general Chinese adult ranges from 0.6% to 0.7% in 2010, that means about 8 million Chinese adults have AF at that time [1-4]. Meanwhile, chronic kidney disease (CKD) has become another important public health problem in China and its prevalence has reached 10.8% in 2010 [5]. With the ever-increasing burden of these two diseases, it seems important to understand the pathological role of AF and CKD towards the clinical adverse outcomes, especially when they are coexistence [6].

Currently, it is well established that AF and CKD are closely related diseases sharing some common risk factors and showing similar adverse outcomes. Studies have shown that AF is one of the independent risk factors towards adverse clinical outcomes like all-cause mortality and stroke in general population and end-stage renal disease (ESRD) patients [7]; AF also has a high incidence and prevalence among the patients with CKD, however, there is still limited data regarding to the potential effect of AF towards adverse outcomes in individuals with CKD [8]. As we mentioned above, there is about 100 million CKD population in China, it is necessary and urgent to make further exploration of this important issue among Chinese CKD individuals.

Therefore, we determine to fill this void by exploring the impact of AF towards adverse outcomes in a large community-based longitudinal cohort of Chinese adults with CKD enrolled in the Kailuan study. We hypothesized that AF would be associated with a higher risk for all-cause mortality and stroke in the population with CKD.

Methods
Study designs and settings
We conducted a population-based prospective cohort study using the health care data repository of the KAILUAN Health and Wellness Registry file (Registration number: ChiCTR-TNRC-11001489), which include 101510 participants starting from 2006. All participants were followed biennially to update information on the potential risk factors and newly diagnosed diseases. The research was performed on the basis of the guidelines from the Helsinki Declaration and was approved by the Ethics Committees of Kailuan General Hospital. The authors obtained written informed consent from the participants before they were enrolled in the study [9, 10].

Study participants
In the current analysis, we used the data repository of the KAILUAN Health and Wellness Registry file to create the study cohort. By the end of December 31, 2015, an initial 101510 participants were recruited in our study, the including criteria were: 1) 45 years old and above; 2) an estimated glomerular filtration rate (eGFR) <60mL/min per 1.73 m², and/or whose proteinuria at entry was defined based on urine dipstick results and quantified as 1+, 2+, 3+, or 4+. The excluding criteria were: 1) participants with a history of kidney transplantation or
dialysis therapies; 2) participants with missing or invalid baseline data, 3) participants with eGFR > 60 mL/min/1.73m² and proteinuria negative. After these exclusions, a total of 21587 men and women 45 years and older with CKD remained in the analysis (Fig 1).

Predictive variable and covariates
As the primary predictor, AF was diagnosed from cohort entry through December 31, 2014. AF was a time-updated exposure. Once a participant developed AF during follow-up, we contributed a person time to the AF exposure group, otherwise, we contributed time to the no AF exposure group before the diagnosis with AF.

Standard 12-lead ECGs were recorded in all participants by strictly standardized Procedures. The ECGs were read and analyzed using the Minnesota ECG classification at the Kaikuan General Hospital reading center by electro-cardiographers [11]. The entry data were used as baseline data, participants provided socio-demographic characteristics and medical history information to a trained interviewer at each clinical examination. Anthropometric measures (e.g. height, weight, waistline, and standardized blood pressure measurements) were
conducted. Hypertension was defined as systolic blood pressure (SBP) greater than 140 mmHg, diastolic blood pressure (DBP) greater than 90 mmHg, or self-reported use of antihypertensive medications. Diabetes was defined as fasting glucose greater than 126 mg/dl, random glucose greater than 200 mg/dl, or use of insulin or other anti-diabetic medication. Blood samples were obtained from all participants following standardized procedures. Serum creatinine and other blood assays such as total cholesterol (TC), LDL cholesterol, HDL cholesterol, triglycerides (TG), novel cardiovascular risk factors (C-reactive protein) were measured at the Kailuan General Hospital Laboratory [10]. The eGFR was calculated by using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation with an adjusted coefficient of 1.1 for the Asian population [12–14] and categorized as >90, 60 to <90, 30 to <60, and <30 mL/min/1.73 m^2. Urine protein was defined based on urine dipstick results and quantified as none/trace, 1+, 2+, 3+, or 4+ [15]. For the multivariate models, blood pressure was included both using a categorical variable and as the systolic and diastolic blood pressure reading.

**Outcomes**

The main outcomes included the all-cause mortality, ischemic stroke and hemorrhagic stroke events. Death information was collected from provincial vital statistics offices. Information on physician-diagnosed stroke events was collected in the biennial interview. To further identify potential stroke events, we also investigated discharge lists from the 11 hospitals. Different types of stroke were diagnosed according to the World Health Organization criteria, based on signs, symptoms, and brain imaging studies from computed tomography or magnetic resonance imaging [8]. Study participants were followed from the entry until the occurrence of the outcome events or until they were censored because of death, loss to follow-up, or the end of the study period on December 31, 2016.

**Statistical analyses**

We used One-way ANOVA and the Chi-square tests to compare continuous and categorical variables, we also use the build-in command in Stata 14.2 to conduct the propensity-score match with demographic and clinical variables to adjust for potential confounding from imbalances in clinical characteristics between individuals with and without AF [16]. Demographic variables included age, sex, education level; clinical variables were smoke use, alcohol intake, hypertension, diabetes mellitus, waist circumference, SBP, DBP, TG, TC, LDL, CRP, and urine protein. Individuals with AF were matched in a 1:4 ratio with those without AF, and differences in clinical characteristics were determined, with P values > 0.1 considered well balanced. After all baseline characteristics were balanced in the propensity-matched model, AF exposure was the only independent variable in our Cox regression model.

We also generated Kaplan-Meier Curve, multivariable Cox proportional hazards regression relating AF to the outcomes of interest among pre- and post- propensity score-matched participants. In the multivariable Cox proportional hazards models, we repeated this analysis after adjusted for the set of covariates at baseline. All statistical tests were evaluated using two-tailed 95% confidence intervals (CI), and data analyses were performed using Stata statistical software version 14.2, and P < 0.05 was treated as statistically significant.

**Results**

**Patient characteristics**

Of the 21587 participants who met the inclusion and exclusion criteria of being aged 45 years or older with CKD, a total of 216 subjects (1.0%) developed ECG-detected AF at the entry of
our cohort study. Then we were able to match 175 AF subjects to 700 Non-AF subjects by using the propensity score match (Fig 1). Baseline characteristics were compared between AF and Non-AF groups in pre- and post-propensity score-matched manner (Table 1). Before matching, participants with AF were older and more likely to have a history of hypertension, larger waistline circumference, and higher TG, TC, and LDL at baseline. After matching, the baseline covariates in the two groups were balanced with no statistically significant differences (Table 1).

### Risk of All-cause mortality and stroke in CKD patients with AF

The median follow-up time was 5.56 years (5.69 ± 1.96). During follow-up, there were 70 cases of death, and 16 cases of ischemic stroke and 6 cases of hemorrhagic stroke that occurred among the participants with AF in comparison with 2572 cases of death and 656 cases of ischemic stroke and 184 cases of hemorrhagic stroke among the participants without AF. Before propensity score matching, AF was associated with higher hazard ratios for all-cause mortality (3.97, 95% CI 3.13 to 5.04) and ischemic stroke (2.91, 95% CI 1.77–4.78) and hemorrhagic

### Table 1. Baseline characteristics according to the presence of AF before and after propensity score matching.

| Characteristic                  | Pre-Propensity Score Match | Post-Propensity Score Match |
|--------------------------------|----------------------------|-----------------------------|
|                                | Non-AF (213) | AF (175) | P value | Non-AF (700) | AF (175) | P value |
| **N**                          | 21371      | 216      |         | 700          | 175      |         |
| **Demographics**               |             |          |         |              |          |         |
| Age (y; mean ± SD)             | 60.85±10.03 | 69.06±9.78 | <0.001 | 68.76±10.26  | 69.00±9.93 | 0.771   |
| Male gender (%)                | 59.94      | 65.19    | 0.055   | 88.86        | 86.29    | 0.342   |
| Education ≤9 years (%)         | 86.40      | 89.19    | 0.270   | 89.06        | 90.57    | 0.672   |
| **Clinical history**           |             |          |         |              |          |         |
| Smoke use (%)                  | 36.27      | 30.58    | 0.091   | 29.43        | 28.57    | 0.824   |
| Alcohol intake (%)             | 26.53      | 35.71    | 0.035   | 28.14        | 26.86    | 0.782   |
| Hypertension (%)               | 23.22      | 29.29    | 0.044   | 30.29        | 28.57    | 0.660   |
| Diabetes (%)                   | 8.69       | 14.60    | 0.009   | 11.57        | 9.71     | 0.486   |
| Myocardial infarction (%)      | 3.04       | 5.09     | 0.037   | 2.29         | 4.57     | 0.102   |
| Congestive heart failure (%)   | 4.11       | 4.17     | 0.051   | 4.72         | 4.76     | 0.924   |
| Peripheral artery disease (%)  | 2.45       | 3.37     | 0.040   | 3.77         | 3.30     | 0.705   |
| Prior strokes (%)              | 3.32       | 5.56     | 0.022   | 5.19         | 5.66     | 0.657   |
| Waistline (cm; mean ± SD)      | 88.06±9.95 | 91.51±11.33 | <0.001 | 91.37±11.45 | 91.21±11.33 | 0.873 |
| SBP (mmHg; mean ± SD)          | 139.51±22.41 | 142.98±21.03 | 0.017 | 144.91±23.21 | 143.15±21.79 | 0.345 |
| DBP (mmHg; mean ± SD)          | 86.91±12.27 | 89.08±12.76 | 0.014 | 89.27±12.84 | 88.03±12.06 | 0.235 |
| LDL cholesterol (mmol/L; mean ± SD) | 2.55±0.78  | 2.85±0.80  | <0.001 | 2.76±0.78  | 2.67±0.85  | 0.233 |
| HDL cholesterol (mmol/L; mean ± SD) | 2.03±0.22  | 2.08±0.17  | 0.788 | 2.04±0.32  | 2.03±0.19  | 0.922 |
| TG (mmol/L; median [IQR])      | 1.43±0.88  | 1.72±1.52  | <0.001 | 1.40±1.05  | 1.44±0.89  | 0.594 |
| TC (mmol/L; median [IQR])      | 4.75±0.99  | 5.08±1.01  | <0.001 | 4.79±0.89  | 4.77±1.00  | 0.828 |
| CRP (mg/L; mean ± SD)          | 3.80±16.55 | 4.60±8.26  | 0.159 | 4.72±7.92  | 4.71±8.65  | 0.994 |
| eGFR (ml/min/1.73m2; mean ± SD) | 67.23±20.25 | 66.62±19.38 | 0.653 | 66.60±19.31 | 66.36±19.60 | 0.881 |
| Urine protein positive (%)     | 50.96      | 57.92     | 0.049   | 51.44        | 53.58     | 0.673   |

Values for categorical variables are given as a number (percentage); for continuous variables, as mean ± standard deviation.

§ Normally distributed variables were compared using the Student’s t-test, and non-normal distributed variables were compared using the Mann-Whitney U test.

Categorical variables are presented as percentages and were compared using the Chi-square test.

Abbreviations: AF, atrial fibrillation; SBP, systolic BP; DBP, diastolic BP; TG, triglycerides. TC, total cholesterol; CRP, C-reactive protein; LDL, low-density lipoprotein; HDL, high-density lipoprotein; eGFR, estimated glomerular filtration rate.

https://doi.org/10.1371/journal.pone.0230189.t001
stroke (3.79, 95% CI 1.68–8.55) compared with that in Non-AF group in unadjusted analyses. After adjusting (Model I = no adjusted; II = adjusted for age, gender; III = adjusted for age, gender, medical history of hypertension and diabetes; IV = adjusted for all covariates except for eGFR and urine protein; V = adjusted for all covariates), the association was slightly affected but observed consistent as before (Table 2).

After propensity score matching, AF was still significantly associated with higher risks of all-cause mortality, ischemic and hemorrhagic stroke events by uni-variable analyses and multi-variable analyses. The difference of all-cause mortality and different types of stroke among Pre- and Post-Propensity Score Matched Participants were also demonstrated by Kaplan-Meier Curves Relating to AF and non-AF group of individuals (Fig 2).

### Discussion

In this community-based longitudinal cohort of Chinese adults with CKD, we found an independent association between AF and increased risks of all-cause mortality and stroke in a subsequent 5-year follow-up, there was an 86% higher risk of all-cause mortality and 104% higher risk of ischemic stroke and 325% higher risk of hemorrhagic stroke in CKD individuals with AF. Furthermore, these associations were still consistent and strong even after strictly propensity score-matched analysis. Although previous literature has shown that AF is an independent risk factor towards these adverse outcomes, most of those studies were performed among western populations, the information from Asian was limited, our data may be beneficial compensatory information in the prevention of AF related adverse outcomes in CKD population.

Previous studies have reported that AF is associated with adverse clinical outcomes in the general population and ESRD patients [17–20]. One of the index studies performed in the

Table 2. Cox proportional hazards analyses of mortality and stroke events among participants with AF before and after propensity score matching.

| Model | Pre–Propensity Score Match | Post–Propensity Score Match |
|-------|-----------------------------|-----------------------------|
|       | Hazard Ratio (95% CI) | P Value | Hazard Ratio (95% CI) | P Value |
| All-cause Mortality | | | | |
| I     | 3.97(3.13–5.04) | <0.001 | 1.78(1.32–2.40) | <0.001 |
| II    | 2.35(1.85–2.98) | <0.001 | 1.92(1.42–2.59) | <0.001 |
| III   | 2.37(1.87–3.02) | <0.001 | 1.92(1.42–2.59) | <0.001 |
| IV    | 2.32(1.78–3.06) | <0.001 | 1.98(1.44–2.73) | <0.001 |
| V     | 1.86(1.33–2.59) | <0.001 | 1.51(1.03–2.22) | 0.036 |
| Ischemic stroke | | | | |
| I     | 2.91(1.77–4.78) | <0.001 | 1.61(1.18–2.83) | 0.001 |
| II    | 2.35(1.43–3.88) | 0.01 | 1.32(1.10–2.86) | 0.01 |
| III   | 2.22(1.33–3.71) | 0.02 | 1.27(1.04–2.76) | 0.018 |
| IV    | 2.23(1.26–3.97) | 0.06 | 1.26(1.03–2.77) | 0.023 |
| V     | 2.04(1.09–3.83) | 0.026 | 1.20(1.02–2.64) | 0.042 |
| Hemorrhagic stroke | | | | |
| I     | 3.79(1.68–8.55) | 0.001 | 2.89(1.29–6.12) | 0.005 |
| II    | 3.69(1.63–8.31) | 0.002 | 1.77(1.20–5.88) | 0.008 |
| III   | 3.59(1.59–8.09) | 0.002 | 1.60(1.10–5.89) | 0.012 |
| IV    | 4.53(2.01–10.23) | <0.001 | 1.87(1.46–6.00) | 0.005 |
| V     | 4.25(1.74–10.36) | 0.001 | 1.65(1.08–5.97) | 0.023 |

I = unadjusted; II = adjusted for age, gender; III = adjusted for age, gender, history of hypertension, diabetes; IV = adjusted for all covariates except for eGFR and urine protein; V = adjusted for all covariates

https://doi.org/10.1371/journal.pone.0230189.t002
general population was from The Framingham Heart Study [21], they examined 5209 general individuals who developed AF and the results showed that AF was associated with a 1.5 fold of increased mortality risk. Another major study was the international Dialysis Outcomes and Practice Patterns Study (DOPPS) which included more than 17000 dialysis patients, AF was also proven to be associated with 28% higher rates of stroke and 16% higher rate of all-cause death [22]. Besides these, the impact of AF towards clinical endpoints in some early stages of CKD also caused attention in recent years. Bansal et al [23] performed an analysis in a group of adults with CKD enrolled in Kaiser Permanente Northern California, among 206229 adults with CKD, 16463 developed incident AF during a 5-year follow-up, the incident AF was proven to be associated with a 67% increase in the rate of ESRD. Sood et al [24] explored the impact of AF towards clinical outcomes like cardiovascular disease and all-cause mortality in patients with a decrease in eGFR, the results showed that Incident AF was associated with a high risk for these adverse outcomes in patients with eGFRs < 90 mL/min per 1.73 m², these difference were more pronounced within the first 6 months of the index date. A recent analysis from the Chronic Renal Insufficiency Cohort (CRIC) Study showed that the incident AF is independently associated with two- to five-fold increased rates of developing subsequent heart failure, myocardial infarction, stroke, or death in adults with CKD [25].

However, all these observational analyses were performed in western populations. In our study based on 21587 Chinese adults with CKD in Kailuan database, we found a higher rate of mortality and stroke among those who developed AF, the AF was associated with 86%, 104% and 325% increase in the rate of death, ischemic stroke and hemorrhagic stroke, respectively. This association was still consistent and strong even after the strict propensity score-matched analysis. Some studies from Asian concerning the pathological role of AF towards outcomes were also performed in general populations. Suzuki et al [26] collected single electrocardiographic AF data from a sample of 13228 Japanese adults in an urban city of Tokyo and found that AF was associated with stroke and all-cause mortality with a nearly 5-year follow-
up. Lee et al [27] conducted a prospective cohort study among 3560 Chinese adults in Taiwan, the results indicated that AF was a significant risk factor for stroke and all-cause death in Chinese adults. However, these results were drawn depending on the epidemiological features of AF in several years ago. As the time goes on, the epidemiological features of CKD and AF might have significantly changed which in turn to have a potential influence on the association between AF and adverse outcomes [7], this is also one of the main reasons that we made our new analysis. Altogether, our results extend these earlier observations to a large Chinese population with CKD and provide more supplementary information in understanding of the potential risk of AF existing in CKD adults. To the best of our knowledge, there are no previous studies that have evaluated the relation between AF and adverse outcomes in such a large number of Chinese CKD patients.

Our study had several strengths. We prospectively explored a very large and diverse sample of community-based Chinese CKD adults 45 years and older in a relatively long time of follow up. We also applied the modified Chinese EPI equation to classified CKD on entry into the study cohort to confirm the different stages of CKD. In order to examine the direct and independent influence of AF towards those adverse endpoints, we also applied propensity score analysis to make each of the available variables between AF and non-AF groups matched. Our study also had several limitations. First, we were unable to determine the exact mechanisms explaining the association between AF and clinical outcomes because the study was an observational cohort. Some potential mediators between AF and adverse outcomes like the hormones in the renin-angiotensin-aldosterone system were not examined, the previous episodes of atrial fibrillation were not recorded in our study and some factors like anticoagulation therapy information were also not included in the dataset, as those treatments might influence the incidence of hemorrhagic stroke, it should be paid great attention while applying them in the patients with CKD, these shortages were hopefully added in our future exploration. Second, we were also not able to quantify accurately the severity of proteinuria because only urine dipstick results were available, this might have a negative influence on the identification of CKD individuals in our study. Third, we could not completely rule out residual confounding, although we applied statistically adjustments for a wide range of potential risk factors, like sex, age, blood pressure, and hemoglobin level. Finally, we performed our study among health plan members within a large community-based individual in northeast China, so our findings may not be completely generalizable to other parts of Chinese populations with CKD.

Conclusion
AF is associated with an 86% higher relative rate of all-cause mortality and 104% that of ischemic stroke and 325% that of hemorrhagic stroke among this group of Chinese adults with CKD, this association is independent of some proved clinical risk factors. Facing the challenge from the combination of these two diseases, future study should focus on elucidating the potential contributing factors which lead to the development of AF in the setting of CKD and potentially modifiable mechanisms through which AF leads to a higher risk of adverse outcomes.

Supporting information
S1 Table. Dataset for basic characteristics and outcomes of the participants in this study. (XLSX)
Acknowledgments

The authors are grateful to all the members of the Kailuan Study team for their contribution and the participants who contributed their data.

Author Contributions

Conceptualization: Shouling Wu, Yang Luo.

Data curation: Chunxia Zhang, Jingli Gao, Aijun Xing, Pengpeng Ye, Shouling Wu.

Formal analysis: Jingli Gao, Aijun Xing, Yuntao Wu.

Investigation: Yidan Guo.

Methodology: Pengpeng Ye.

References

1. Li Y, Wu YF, Chen KP, Li X, Zhang X, Xie GQ, et al. Prevalence of atrial fibrillation in China and its risk factors. Biomed Environ Sci. 2013; 26 (9):709–16. https://doi.org/10.3967/0895-3988.2013.09.001 PMID: 24099604

2. Guo Y, Tian Y, Wang H, Si Q, Wang Y, GYH L. Prevalence, incidence, and lifetime risk of atrial fibrillation in China: new insights into the global burden of atrial fibrillation. Chest. 2015; 147 (1):109–19. https://doi.org/10.1378/chest.14-0321 PMID: 24921459

3. Voroneanu L, Ortiz A, Nistor I, Covic A. Atrial fibrillation in chronic kidney disease. Eur J Intern Med. 2016; 33:3–13. https://doi.org/10.1016/j.ejim.2016.04.007 PMID: 2715803

4. Chugh SS, Havmoeller R, Narayan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014; 129 (8):837–47. https://doi.org/10.1161/CIRCULATIONAHA.113.005119 PMID: 24345399

5. Zhang L, Wang F, Wang L, Wang W, Liu B, Liu J, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet. 2012; 379 (9818):815–22. https://doi.org/10.1016/S0140-6736(12)60033-6 PMID: 22386035

6. Alonso A, Lopez FL, Matsushita K, Loehr LR, Agarwal SK, Chen LY, et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2011; 123 (25):2946–53. https://doi.org/10.1161/CIRCULATIONAHA.111.005119 PMID: 21646496

7. Rahman F, Kwan GF, Benjamin EJ. Global epidemiology of atrial fibrillation. Nat Rev Cardiol. 2014; 11 (11):639–54. https://doi.org/10.1038/nrcardio.2014.3 PMID: 25113750

8. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001; 285 (18):2370–5. https://doi.org/10.1001/jama.285.18.2370 PMID: 11943485

9. Jin C, Li G, Rexrode KM, Gurol ME, Yuan X, Hui Y, et al. Prospective Study of Fasting Blood Glucose and Intracerebral Hemorrhagic Risk. Stroke. 2018; 49 (1):27–33. https://doi.org/10.1161/STROKEAHA.117.019189 PMID: 29229723

10. Wu Y, Yu J, Jin C, Li Y, Su J, Wei G, et al. Longitudinal fasting blood glucose patterns and arterial stiffness risk in a population without diabetes. PLOS ONE. 2017; 12 (11):e0188423. https://doi.org/10.1371/journal.pone.0188423 PMID: 29155890

11. Seipel L, Kuhlkamp V. Electrocardiographic diagnosis of atrial fibrillation and flutter. Z Kardiol. 1994; 83 Suppl 5:29–34.

12. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150 (9):604–12. https://doi.org/10.7326/0003-4819-150-9-200905050-00006 PMID: 19414839

13. Teo BW, Xu H, Wang D, Li J, Sinha AK, Shuter B, et al. GFR estimating equations in a multiethnic Asian population. Am J Kidney Dis. 2011; 58 (1):56–63. https://doi.org/10.1053/j.ajkd.2011.02.393 PMID: 21601325

14. Hoste L, Dubourg L, Selistre L, De Souza VC, Ranchin B, Hadji-Aissa A, et al. A new equation to estimate the glomerular filtration rate in children, adolescents and young adults. Nephrol Dial Transplant. 2014; 29 (5):1082–91. https://doi.org/10.1093/ndt/gft277 PMID: 24046193
15. Baber U, Howard VJ, Halperin JL, Soliman EZ, Zhang X, McClellan W, et al. Association of chronic kidney disease with atrial fibrillation among adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Circ Arrhythm Electrophysiol. 2011; 4 (1):26–32. https://doi.org/10.1161/CIRCEP.110.957100 PMID: 21076159

16. Garrido MM, Kelley AS, Paris J, Roza K, Meier DE, Morrison RS, et al. Methods for constructing and assessing propensity scores. Health Serv Res. 2014; 49 (5):1701–20. https://doi.org/10.1111/1475-6773.12182 PMID: 24779867

17. Bhatia HS, AUID Oho, Hsu JC, AUID Oho, Kim RJ. Atrial fibrillation and chronic kidney disease: A review of options for therapeutic anticoagulation to reduce thromboembolism risk. Clin Cardiol. 2018; 41 (10):1395–402. https://doi.org/10.1002/clc.23085 PMID: 30259531

18. Conen D, Chae CU, Glynn RJ, Tedrow UB, Everett BM, Buring JE, et al. Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. JAMA. 2011; 305 (20):2080–7. https://doi.org/10.1001/jama.2011.659 PMID: 21610240

19. Wilson LE, AUID Oho, Luo X, Li X, Mardekan J, Garcia RAB, et al. Clinical outcomes and treatment patterns among Medicare patients with nonvalvular atrial fibrillation (NVAF) and chronic kidney disease. PLOS ONE. 2019; 14 (11):e0225052. https://doi.org/10.1371/journal.pone.0225052 PMID: 31725743

20. Bose A, O’Neal WT, Wu C, McClure LA, Judd SE, Howard VJ, et al. Sex Differences in Risk Factors for Incident Atrial Fibrillation (from the Reasons for Geographic and Racial Differences in Stroke [REGARDS] Study). Am J Cardiol. 2019; 123 (9):1453–7. https://doi.org/10.1016/j.amjcard.2019.01.056 PMID: 30771899

21. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991; 22 (8):983–8. https://doi.org/10.1161/01.str.22.8.983 PMID: 1866765

22. Wizemann V, Tong L, Satayathum S, Disney A, Akiba T, Fissell RB, et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int. 2010; 77 (12):1098–106. https://doi.org/10.1038/ki.2009.477 PMID: 20054291

23. Bansal N, Fan D, Hsu CY, Ordonez JD, Marcus GM, Go AS. Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease. Circulation. 2013; 127 (5):569–74. https://doi.org/10.1161/CIRCULATIONAHA.112.123992 PMID: 23275377

24. Massicotte-Azarmiouch D, Kuwornu JP, Carrero JJ, Lam NN, Molnar AO, Zimmerman D, et al. Incident Atrial Fibrillation and the Risk of Congestive Heart Failure, Myocardial Infarction, End-Stage Kidney Disease, and Mortality Among Patients With a Decreased Estimated GFR. Am J Kidney Dis. 2018; 71 (2):181–9. https://doi.org/10.1053.j.ajkd.2017.08.016 PMID: 29153994

25. Bansal N, Xie D, Sha D, Appel LJ, Deo R, Feldman HI, et al. Cardiovascular Events after New-Onset Atrial Fibrillation in Adults with CKD: Results from the Chronic Renal Insufficiency Cohort (CRIC) Study. J Am Soc Nephrol. 2018; 29 (12):2859–69. https://doi.org/10.1681/ASN.2018050514 PMID: 30377231

26. Suzuki S, Yamashita T, Otsuka T, Sagara K, Uejima T, Okawa Y, et al. Recent mortality of Japanese patients with atrial fibrillation in an urban city of Tokyo. J Cardiol. 2011; 58 (2):116–23. https://doi.org/10.1016/j.jjcc.2011.06.006 PMID: 21820280

27. Chien KL, Su TC, Hsu HC, Chang WT, Chen PC, Chen MF, et al. Atrial fibrillation prevalence, incidence and risk of stroke and all-cause death among Chinese. Int J Cardiol. 2010; 139 (2):173–80. https://doi.org/10.1016/j.ijcard.2008.10.045 PMID: 19046608